News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Demand normalisation post the second wave contributed to the steady growth
Anti-malaria API facility will be operational in 15-18 months
The company has strong product launches both in India and overseas
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has tied up with OrbiMed as a financial partner for global reach
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Deal signed with AOP Orphan for US commercial rights
The drug is indicated for mild and transient episodes of heart block
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Subscribe To Our Newsletter & Stay Updated
